Arete Wealth Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-47,660
| Closed | -$5.81M | – | 755 |
|
|
2025
Q4 | $5.81M | Buy |
47,660
+27,986
| +142% | +$3.21M | 0.35% | 62 |
|
|
2025
Q3 | $1.97M | Sell |
19,674
-9
| -0% | -$811 | 0.12% | 168 |
|
|
2025
Q2 | $1.63M | Sell |
19,683
-279
| -1% | -$22.3K | 0.12% | 183 |
|
|
2025
Q1 | $1.62M | Buy |
19,962
+42
| +0.2% | +$3.75K | 0.12% | 170 |
|
|
2024
Q4 | $1.79M | Sell |
19,920
-238
| -1% | -$23.1K | 0.13% | 167 |
|
|
2024
Q3 | $1.98M | Sell |
20,158
-1,698
| -8% | -$167K | 0.17% | 121 |
|
|
2024
Q2 | $2.01M | Buy |
21,856
+440
| +2% | +$39.5K | 0.17% | 126 |
|
|
2024
Q1 | $2.03M | Sell |
21,416
-26
| -0.1% | -$2.41K | 0.19% | 128 |
|
|
2023
Q4 | $1.91M | Buy |
+21,442
| New | +$1.59M | 0.15% | 145 |
|
|
2023
Q3 | – | Sell |
-6,974
| Closed | -$580K | – | 737 |
|
|
2023
Q2 | $580K | Sell |
6,974
-27
| -0.4% | -$2.26K | 0.05% | 332 |
|
|
2023
Q1 | $534K | Buy |
7,001
+505
| +8% | +$41.9K | 0.04% | 332 |
|
|
2022
Q4 | $539M | Buy |
6,496
+33
| +0.5% | +$2.67K | 0.05% | 314 |
|
|
2022
Q3 | $513K | Sell |
6,463
-8,867
| -58% | -$748K | 0.05% | 292 |
|
|
2022
Q2 | $1.18M | Buy |
15,330
+8,376
| +120% | +$629K | 0.12% | 130 |
|
|
2022
Q1 | $625K | Buy |
6,954
+45
| +0.7% | +$4.16K | 0.05% | 244 |
|
|
2021
Q4 | $769K | Sell |
6,909
-1,239
| -15% | -$149K | 0.07% | 218 |
|
|
2021
Q3 | $1.03M | Buy |
8,148
+140
| +2% | +$18K | 0.11% | 165 |
|
|
2021
Q2 | $1.02M | Buy |
8,008
+355
| +5% | +$46.7K | 0.14% | 137 |
|
|
2021
Q1 | $1.05M | Sell |
7,653
-596
| -7% | -$89.2K | 0.13% | 155 |
|
|
2020
Q4 | $1.16M | Sell |
8,249
-4,906
| -37% | -$628K | 0.16% | 133 |
|
|
2020
Q3 | $1.46M | Buy |
13,155
+4,946
| +60% | +$554K | 0.22% | 109 |
|
|
2020
Q2 | $919K | Buy |
8,209
+4,212
| +105% | +$415K | 0.16% | 153 |
|
|
2020
Q1 | $310K | Sell |
3,997
-633
| -14% | -$56.1K | 0.06% | 239 |
|
|
2019
Q4 | $440K | Buy |
4,630
+225
| +5% | +$19.5K | 0.08% | 250 |
|
|
2019
Q3 | $336K | Hold |
4,405
| – | – | 0.06% | 278 |
|
|
2019
Q2 | $386K | Sell |
4,405
-119
| -3% | -$10.2K | 0.07% | 261 |
|
|
2019
Q1 | $410K | Buy |
4,524
+253
| +6% | +$21.5K | 0.09% | 239 |
|
|
2018
Q4 | $306K | Sell |
4,271
-3,107
| -42% | -$250K | 0.07% | 269 |
|
|
2018
Q3 | $707K | Buy |
7,378
+566
| +8% | +$54.9K | 0.16% | 153 |
|
|
2018
Q2 | $648K | Hold |
6,812
| – | – | 0.15% | 160 |
|
|
2018
Q1 | $598K | Buy |
6,812
+110
| +2% | +$10K | 0.2% | 138 |
|
|
2017
Q4 | $569K | Buy |
6,702
+791
| +13% | +$66.3K | 0.19% | 150 |
|
|
2017
Q3 | $512K | Buy |
5,911
+1,862
| +46% | +$149K | 0.2% | 147 |
|
|
2017
Q2 | $312K | Buy |
+4,049
| New | +$287K | 0.14% | 183 |
|
Other funds holding XBI
Arete Wealth Advisors's XBI Position: Q1 2026 in Review
Arete Wealth Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 47,660 shares — an estimated $5.81M sold.
Arete Wealth Advisors first reported a position in XBI in Q2 2017 and held it in 34 quarters. The position peaked at $539M in Q4 2022. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Arete Wealth Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
- Arete Wealth Advisors sold 47,660 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $5.81M.
- Arete Wealth Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2017 and held it in 34 quarters.
- Arete Wealth Advisors's State Street SPDR S&P Biotech ETF position peaked at $539M in Q4 2022.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Arete Wealth Advisors's 13F filing for Q1 2026, filed 18 May 2026.